BRIEF COMMUNICATION

Pre-gestational diabetes during the COVID-19 pandemic in Bergamo, Italy

Alessandro Roberto Dodesini¹,*, Silvia Galliani¹, Elena Ciriello², Rosalia Bellante¹,
Roberto Trevisan¹
¹Endocrinology and Diabetes Unit, ASST Papa Giovanni XXIII, Bergamo, Italy
²Gynecology and Obstetric Unit, ASST Papa Giovanni XXIII, Bergamo, Italy

*CORRESPONDENCE
Alessandro Roberto Dodesini, Endocrinology and Diabetes Unit, ASST Papa Giovanni
XXIII, 24127, Bergamo, Italy.
Email: adodesini@asst-pg23.it

KEYWORDS
Bergamo; COVID-19; Pre-gestational diabetes

SYNOPSIS
Effective enforcement of lockdown measures, use of technology, and implementation of
telemedicine may have significantly reduced the number of diabetic pregnant women who
tested positive for COVID-19 in Bergamo, Italy.

The COVID-19 pandemic has caused the proliferation of a highly contagious and
frequently fatal pneumonia around the world.[1] COVID-19 has severely affected Italy,
and at the onset of this crisis, Bergamo, a city in northern Italy, regularly reported the
highest number of cases in the country for many weeks. During outbreaks of infectious
disease, pregnant women represent a high-risk population due to their increased
susceptibility to infections, particularly when comorbidities such as pre-gestational
diabetes (present in 0.5% of pregnant populations) are present.[2,3] Few data are

This article has been accepted for publication and undergone full peer review but has not been
through the copyediting, typesetting, pagination and proofreading process, which may lead to
differences between this version and the Version of Record. Please cite this article as doi:
10.1002/IJGO.13306

This article is protected by copyright. All rights reserved
available on pregnant women with pre-gestational diabetes during the COVID-19 pandemic.

From February 22 to May 17, 2020, all new-onset pregnant women with pre-gestational diabetes (nine with Type 1 [DMT1] and five with Type 2 diabetes) were screened for COVID-19 in the Diabetic and Pregnancy Clinic of Papa Giovanni XXIII Hospital in Bergamo. Their average age was 35±5 years (mean±SD), BMI 29.1±5.6 kg/m², A1c 43±8 mmol/mol and diabetes duration 10±8 years (with longer disease duration in DMT1 patients \( P=0.05 \)).

All patients used continuous glucose monitoring (CGM) for glucose control and telehealth was implemented in order to monitor glycemic trends at home.[4]

Retrospective observational studies not involving drugs do not require ethics committee approval and written informed consent in our institution.

Two pregnant women with DTM1 had a positive SARS-CoV-2 swab. One patient at 28 weeks of pregnancy with cough was hospitalized for COVID-19 pneumonia and was treated with hydroxychloroquine, antibiotic and antiviral therapy, and antithrombotic prophylaxis. A month later, the symptoms have regressed and the swab has returned negative for COVID-19. Mean daily glycemia, measured by CGM, was higher in both women when compared to that of women with negative COVID-19 swabs (134±4 vs 108±2 mg/dl, \( P=0.03 \)).

Although false negative tests are a possible risk factor, our screening procedure in all patients with pre-gestational diabetes during pregnancy revealed a prevalence of 14% for COVID-19, much less than that of the general population in the Bergamo area, estimated to be around 30–35% (unpublished data from Instituto Superiore di Sanità).

In spite of the small sample size, our results indicate that, after the onset of pregnancy, the combination of lockdown measures with the use of technology (especially CGM) and implementation of telehealth may have contributed to the relatively small number of pregnant women with pre-gestational diabetes who tested positive for COVID-19 in Bergamo, Italy. The observations of the present study could help colleagues in the management of pregnancy in women with pre-gestational diabetes during the COVID-19 pandemic.

**AUTHOR CONTRIBUTIONS**

This article is protected by copyright. All rights reserved
ARD designed and coordinated the study, wrote, and revised the manuscript; SG, EC and RB enrolled patients and analyzed data; RT edited and revised the manuscript. All authors have contributed to and approved of the final version of the manuscript.

ACKNOWLEDGEMENTS
The authors acknowledge all of the women who participated in the study and the staff of the metabolic and obstetric units.

CONFLICTS OF INTEREST
The authors have no conflicts of interest.

REFERENCES